Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
PharmaTher Holdings Ltd ( (TSE:PHRM) ) has provided an update.
PharmaTher Holdings Ltd. announced a strategic expansion of its PharmaPatch microneedle patch platform into GLP-1 therapies aimed at treating obesity, building on preclinical progress and design know-how from its ketamine and psychedelic patch programs. The company plans to develop a needle-free, at-home, long-acting GLP-1 patch, potentially offering up to one month of sustained drug delivery, targeting a rapidly growing U.S. obesity treatment market projected to more than quadruple by 2030, and it is advancing feasibility, preclinical work and related patent protection to secure a differentiated position in this high-growth segment.
The most recent analyst rating on (TSE:PHRM) stock is a Sell with a C$0.10 price target. To see the full list of analyst forecasts on PharmaTher Holdings Ltd stock, see the TSE:PHRM Stock Forecast page.
Spark’s Take on TSE:PHRM Stock
According to Spark, TipRanks’ AI Analyst, TSE:PHRM is a Neutral.
Overall score is held down primarily by weak financial performance (pre-revenue, ongoing losses/negative cash flow, shrinking equity) and bearish technical signals (below major moving averages with negative MACD). Positive corporate events (asset sale and program focus) provide some offset, but valuation support is limited given negative earnings and no dividend yield provided.
To see Spark’s full report on TSE:PHRM stock, click here.
More about PharmaTher Holdings Ltd
PharmaTher Holdings Ltd. is a specialty pharmaceutical company focused on unlocking the therapeutic potential of ketamine, psychedelics and GLP-1 drugs for neuropsychiatric and obesity disorders. Its core assets include the KETARx portfolio of ketamine drugs and data, the PharmaPatch microneedle patch platform for transdermal delivery, and a 49% stake in Sairiyo Therapeutics, which is developing an oral cepharanthine formulation for infectious diseases and cancer.
Average Trading Volume: 107,568
Technical Sentiment Signal: Sell
Current Market Cap: C$8.65M
For an in-depth examination of PHRM stock, go to TipRanks’ Overview page.